These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38687678)

  • 1. Loss of tumor suppressor TMEM127 drives RET-mediated transformation through disrupted membrane dynamics.
    Walker TJ; Reyes-Alvarez E; Hyndman BD; Sugiyama MG; Oliveira LCB; Rekab AN; Crupi MJF; Cabral-Dias R; Guo Q; Dahia PLM; Richardson DS; Antonescu CN; Mulligan LM
    Elife; 2024 Apr; 12():. PubMed ID: 38687678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Tumour Suppressor TMEM127 Drives RET-mediated Transformation Through Disrupted Membrane Dynamics.
    Walker TJ; Reyes-Alvarez E; Hyndman BD; Sugiyama MG; Oliveira LCB; Rekab AN; Crupi MJF; Cabral-Dias R; Guo Q; Dahia PLM; Richardson DS; Antonescu CN; Mulligan LM
    bioRxiv; 2024 Apr; ():. PubMed ID: 37425958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMEM127 suppresses tumor development by promoting RET ubiquitination, positioning, and degradation.
    Guo Q; Cheng ZM; Gonzalez-Cantú H; Rotondi M; Huelgas-Morales G; Ethiraj P; Qiu Z; Lefkowitz J; Song W; Landry BN; Lopez H; Estrada-Zuniga CM; Goyal S; Khan MA; Walker TJ; Wang E; Li F; Ding Y; Mulligan LM; Aguiar RCT; Dahia PLM
    Cell Rep; 2023 Sep; 42(9):113070. PubMed ID: 37659079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Characterization of TMEM127 Variants Reveals Novel Insights into Its Membrane Topology and Trafficking.
    Flores SK; Deng Y; Cheng Z; Zhang X; Tao S; Saliba A; Chu I; Burnichon N; Gimenez-Roqueplo AP; Wang E; Aguiar RCT; Dahia PLM
    J Clin Endocrinol Metab; 2020 Sep; 105(9):e3142-56. PubMed ID: 32575117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
    Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
    Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TMEM127 human tumor suppressor is a component of the mTORC1 lysosomal nutrient-sensing complex.
    Deng Y; Qin Y; Srikantan S; Luo A; Cheng ZM; Flores SK; Vogel KS; Wang E; Dahia PLM
    Hum Mol Genet; 2018 May; 27(10):1794-1808. PubMed ID: 29547888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RET ligand-induced internalization and its consequences for downstream signaling.
    Richardson DS; Lai AZ; Mulligan LM
    Oncogene; 2006 May; 25(22):3206-11. PubMed ID: 16418724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice.
    Lai EW; Rodriguez OC; Aventian M; Cromelin C; Fricke ST; Martiniova L; Lubensky IA; Lisanti MP; Picard KL; Powers JF; Tischler AS; Pacak K; Albanese C
    Cell Cycle; 2007 Aug; 6(15):1946-50. PubMed ID: 17671425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct Temporal Regulation of RET Isoform Internalization: Roles of Clathrin and AP2.
    Crupi MJ; Yoganathan P; Bone LN; Lian E; Fetz A; Antonescu CN; Mulligan LM
    Traffic; 2015 Nov; 16(11):1155-73. PubMed ID: 26304132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.
    Yao L; Schiavi F; Cascon A; Qin Y; Inglada-Pérez L; King EE; Toledo RA; Ercolino T; Rapizzi E; Ricketts CJ; Mori L; Giacchè M; Mendola A; Taschin E; Boaretto F; Loli P; Iacobone M; Rossi GP; Biondi B; Lima-Junior JV; Kater CE; Bex M; Vikkula M; Grossman AB; Gruber SB; Barontini M; Persu A; Castellano M; Toledo SP; Maher ER; Mannelli M; Opocher G; Robledo M; Dahia PL
    JAMA; 2010 Dec; 304(23):2611-9. PubMed ID: 21156949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma.
    Burnichon N; Lepoutre-Lussey C; Laffaire J; Gadessaud N; Molinié V; Hernigou A; Plouin PF; Jeunemaitre X; Favier J; Gimenez-Roqueplo AP
    Eur J Endocrinol; 2011 Jan; 164(1):141-5. PubMed ID: 20923864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homozygous TMEM127 mutations in 2 patients with bilateral pheochromocytomas.
    Eijkelenkamp K; Olderode-Berends MJW; van der Luijt RB; Robledo M; van Dooren M; Feelders RA; de Vries J; Kerstens MN; Links TP; van der Horst-Schrivers ANA
    Clin Genet; 2018 May; 93(5):1049-1056. PubMed ID: 29282712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
    Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
    Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RET expression and neuron-like differentiation of pheochromocytoma and normal chromaffin cells.
    Powers JF; Picard KL; Tischler AS
    Horm Metab Res; 2009 Sep; 41(9):710-4. PubMed ID: 19551609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma.
    Abermil N; Guillaud-Bataille M; Burnichon N; Venisse A; Manivet P; Guignat L; Drui D; Chupin M; Josseaume C; Affres H; Plouin PF; Bertherat J; Jeunemaître X; Gimenez-Roqueplo AP
    J Clin Endocrinol Metab; 2012 May; 97(5):E805-9. PubMed ID: 22419703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.
    Cassinelli G; Favini E; Degl'Innocenti D; Salvi A; De Petro G; Pierotti MA; Zunino F; Borrello MG; Lanzi C
    Neoplasia; 2009 Jan; 11(1):10-21. PubMed ID: 19107227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential membrane compartmentalization of Ret by PTB-adaptor engagement.
    Lundgren TK; Luebke M; Stenqvist A; Ernfors P
    FEBS J; 2008 May; 275(9):2055-66. PubMed ID: 18355321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GGA3-mediated recycling of the RET receptor tyrosine kinase contributes to cell migration and invasion.
    Crupi MJF; Maritan SM; Reyes-Alvarez E; Lian EY; Hyndman BD; Rekab AN; Moodley S; Antonescu CN; Mulligan LM
    Oncogene; 2020 Feb; 39(6):1361-1377. PubMed ID: 31645646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
    Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
    Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC).
    Kim DW; Chung HK; Park KC; Hwang JH; Jo YS; Chung J; Kalvakolanu DV; Resta N; Shong M
    Mol Endocrinol; 2007 Dec; 21(12):3039-49. PubMed ID: 17761947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.